Mavacoxib in Dogs
Generic: Mavacoxib
Mavacoxib is a long-acting, non-steroidal anti-inflammatory drug (NSAID) specifically designed for the once-monthly treatment of pain and inflammation associated with osteoarthritis in dogs.
This medication is intended for dogs.
Overview
Mavacoxib represents a specialized category of veterinary therapeutics known as long-acting coxib-class NSAIDs. Unlike traditional daily medications such as Aspirin, which require multiple administrations per day, Mavacoxib is engineered to provide a steady-state therapeutic effect over the course of an entire month. It is indicated exclusively for the long-term management of chronic musculoskeletal pain, allowing veterinarians to maintain consistent relief for canine patients suffering from degenerative joint conditions. While it shares functional goals with steroidal anti-inflammatories like Cortisone or Prednisone, it operates through a distinct non-steroidal pathway, thereby avoiding the profound metabolic side effects often associated with systemic steroid therapy.
In clinical practice, this medication is typically reserved for dogs that have already reached skeletal maturity and require extended management of osteoarthritis. Because its duration of action is significantly longer than alternatives like Firocoxib, clinicians prioritize strict adherence to dosing protocols. It is not intended for acute injury or post-operative pain management where short-term, easily reversible control is required. Furthermore, when compared to the targeted anti-inflammatory effects of Betamethasone or Methylprednisolone, Mavacoxib provides superior localized joint comfort without the immunosuppressive risks typically linked to prolonged corticosteroid usage.
The clinical integration of Mavacoxib requires careful pre-treatment assessment, including baseline blood chemistry and liver enzyme analysis. Veterinarians use this medication to bridge the gap between reactive pain relief and maintenance therapy, often serving as a cornerstone in multimodal management plans. By reducing prostaglandin production in the joint space, it helps mitigate the inflammation that exacerbates cartilage degradation, allowing for improved mobility in geriatric canines. It serves as a vital component for chronic disease management, distinct from the short-term protocols involving Hydrocortisone, ensuring that the quality of life remains high for dogs with progressive orthopedic disease.
What It Treats
- Osteoarthritis: Specifically used for the chronic control of pain and inflammation in degenerative joint diseases.
- Musculoskeletal Pain: Provides relief for symptomatic joint stiffness and reduced range of motion in adult dogs.
- Chronic Mobility Impairment: Helps improve weight-bearing ability in dogs experiencing structural joint changes.
How It Works
Mavacoxib functions by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme. In a healthy or injured state, COX-2 is responsible for producing prostaglandins, which are lipid compounds that signal pain, facilitate inflammation, and induce fever. By blocking this specific enzyme, Mavacoxib prevents the inflammatory cascade from escalating within the joint capsule. Because it targets COX-2 more specifically than COX-1, it helps preserve the protective prostaglandins that support gastric mucosal integrity and renal blood flow. This pharmacological selectivity is the hallmark of the coxib class, allowing for more targeted relief. The extended half-life of Mavacoxib is due to its slow metabolism, which allows the therapeutic concentration to remain stable in the dog's system for approximately 30 days after a single oral dose.
Dosage
Mavacoxib is strictly dosed based on the dog's body weight, typically at a rate of 2 mg per kg. Following the initial dose, a second dose is administered 14 days later, after which the medication is given at monthly intervals. Never adjust the dose without veterinary supervision, as the long-acting nature of the drug makes it impossible to quickly reverse if an overdose occurs.
Administration
Mavacoxib should be administered with a meal to minimize the risk of gastrointestinal irritation. It comes in a flavored chewable tablet that most dogs accept readily. Ensure the dog consumes the entire dose, and verify that the administration schedule follows the precise 14-day initial interval followed by a 30-day maintenance interval.
Storage
Store the medication in its original blister packaging at room temperature, generally between 15°C and 25°C (59°F to 77°F). Keep the product out of reach of children and pets. Do not remove the tablet from the blister pack until the moment of administration, as environmental exposure may affect stability.
Contraindications
Mavacoxib should not be administered to dogs younger than 12 months of age or those weighing less than 3 kg, as safety has not been established in these populations. It is strictly contraindicated in dogs with pre-existing gastrointestinal ulceration, inflammatory bowel disease, or severe renal or hepatic impairment. Furthermore, it must never be used in conjunction with other NSAIDs or corticosteroid therapies, as the cumulative effect significantly increases the risk of life-threatening gastrointestinal perforation or renal failure. Pregnant or lactating bitches should not receive this medication, and it should be avoided in dogs with known hypersensitivity to sulfonamides.
Interactions
Concurrent use with other NSAIDs is strictly prohibited due to the risk of additive toxicity. Additionally, Mavacoxib must not be given alongside corticosteroids, as this combination greatly elevates the risk of severe gastric ulceration. Care should also be taken when administering drugs that affect renal blood flow or are highly protein-bound, such as certain anticoagulants or diuretics. If a transition from another NSAID is necessary, a washout period is required to prevent adverse drug interactions, which must be determined by a veterinarian.
Side Effects
- Vomiting and diarrhea
- Loss of appetite (anorexia)
- Increased thirst (polydipsia) and urination (polyuria)
- Lethargy or changes in behavior
- Gastrointestinal ulceration (serious)
- Renal (kidney) dysfunction (serious)
- Hepatic (liver) enzyme elevation (serious)
Sources & References
Frequently Asked Questions
This information is educational only and not a substitute for professional veterinary advice. Always consult a licensed veterinarian before starting or changing any medication.
